Literature DB >> 18195006

Human major histocompatibility complex (MHC) class I molecules with disulfide traps secure disease-related antigenic peptides and exclude competitor peptides.

Steven M Truscott1, Xiaoli Wang, Lonnie Lybarger, William E Biddison, Cortez McBerry, John M Martinko, Janet M Connolly, Gerald P Linette, Daved H Fremont, Ted H Hansen, Beatriz M Carreno.   

Abstract

The ongoing discovery of disease-associated epitopes detected by CD8 T cells greatly facilitates peptide-based vaccine approaches and the construction of multimeric soluble recombinant proteins (e.g. tetramers) for isolation and enumeration of antigen-specific CD8 T cells. Related to these outcomes of epitope discovery is the recent demonstration that MHC class I/peptide complexes can be expressed as single chain trimers (SCTs) with peptide, beta(2)m and heavy chain connected by linkers to form a single polypeptide chain. Studies using clinically relevant mouse models of human disease have shown that SCTs expressed by DNA vaccination are potent stimulators of cytotoxic T lymphocytes. Their vaccine efficacy has been attributed to the fact that SCTs contain a preprocessed and preloaded peptide that is stably displayed on the cell surface. Although SCTs of HLA class I/peptide complexes have been previously reported, they have not been characterized for biochemical stability or susceptibility to exogenous peptide binding. Here we demonstrate that human SCTs remain almost exclusively intact when expressed in cells and can incorporate a disulfide trap that dramatically excludes the binding of exogenous peptides. The mechanistic and practical applications of these findings for vaccine development and T cell isolation/enumeration are discussed.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18195006      PMCID: PMC2276332          DOI: 10.1074/jbc.M709935200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  55 in total

1.  Definition and transfer of a serological epitope specific for peptide-empty forms of MHC class I.

Authors:  Y Y Yu; N B Myers; C M Hilbert; M R Harris; G K Balendiran; T H Hansen
Journal:  Int Immunol       Date:  1999-12       Impact factor: 4.823

Review 2.  The cutting edge of spondylarthropathy research in the millennium.

Authors:  Kaisa Granfors; Elisabeth Märker-Hermann; Filip de Keyser; Muhammad A Khan; Eric M Veys; David T Y Yu
Journal:  Arthritis Rheum       Date:  2002-03

3.  Cutting edge: single-chain trimers of MHC class I molecules form stable structures that potently stimulate antigen-specific T cells and B cells.

Authors:  Yik Y L Yu; Nikolai Netuschil; Lonnie Lybarger; Janet M Connolly; Ted H Hansen
Journal:  J Immunol       Date:  2002-04-01       Impact factor: 5.422

4.  Class I negative CD8 T cells reveal the confounding role of peptide-transfer onto CD8 T cells stimulated with soluble H2-Kb molecules.

Authors:  Eckart Schott; Nicolas Bertho; Qing Ge; Madelon M Maurice; Hidde L Ploegh
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-08       Impact factor: 11.205

5.  Soluble peptide-MHC monomers cause activation of CD8+ T cells through transfer of the peptide to T cell MHC molecules.

Authors:  Qing Ge; Jennifer D Stone; M Todd Thompson; Jennifer R Cochran; Mia Rushe; Herman N Eisen; Jianzhu Chen; Lawrence J Stern
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-08       Impact factor: 11.205

6.  Peptide-beta2-microglobulin-MHC fusion molecules bind antigen-specific T cells and can be used for multivalent MHC-Ig complexes.

Authors:  Tim F Greten; Firouzeh Korangy; Gunnar Neumann; Heiner Wedemeyer; Karola Schlote; Astrid Heller; Stephan Scheffer; Drew M Pardoll; Annette I Garbe; Jonathan P Schneck; Michael P Manns
Journal:  J Immunol Methods       Date:  2002-12-20       Impact factor: 2.303

7.  Quantitating protein synthesis, degradation, and endogenous antigen processing.

Authors:  Michael F Princiotta; Diana Finzi; Shu-Bing Qian; James Gibbs; Sebastian Schuchmann; Frank Buttgereit; Jack R Bennink; Jonathan W Yewdell
Journal:  Immunity       Date:  2003-03       Impact factor: 31.745

8.  MHC allele-specific molecular features determine peptide/HLA-A2 conformations that are recognized by HLA-A2-restricted T cell receptors.

Authors:  Zichun Wang; Richard Turner; Brian M Baker; William E Biddison
Journal:  J Immunol       Date:  2002-09-15       Impact factor: 5.422

9.  Kb, Kd, and Ld molecules share common tapasin dependencies as determined using a novel epitope tag.

Authors:  N B Myers; M R Harris; J M Connolly; L Lybarger; Y Y Yu; T H Hansen
Journal:  J Immunol       Date:  2000-11-15       Impact factor: 5.422

10.  Interactions of HLA-B27 with the peptide loading complex as revealed by heavy chain mutations.

Authors:  M R Harris; L Lybarger; N B Myers; C Hilbert; J C Solheim; T H Hansen; Y Y Yu
Journal:  Int Immunol       Date:  2001-10       Impact factor: 4.823

View more
  10 in total

Review 1.  Properties and applications of single-chain major histocompatibility complex class I molecules.

Authors:  Eleni Kotsiou; Joanna Brzostek; Keith G Gould
Journal:  Antioxid Redox Signal       Date:  2011-03-31       Impact factor: 8.401

2.  Single chain MHC I trimer-based DNA vaccines for protection against Listeria monocytogenes infection.

Authors:  Sojung Kim; Adam Zuiani; Javier A Carrero; Ted H Hansen
Journal:  Vaccine       Date:  2012-01-26       Impact factor: 3.641

3.  Single-chain HLA-A2 MHC trimers that incorporate an immundominant peptide elicit protective T cell immunity against lethal West Nile virus infection.

Authors:  Sojung Kim; Lijin Li; Curtis P McMurtrey; William H Hildebrand; Jon A Weidanz; William E Gillanders; Michael S Diamond; Ted H Hansen
Journal:  J Immunol       Date:  2010-03-08       Impact factor: 5.422

4.  Engineering superior DNA vaccines: MHC class I single chain trimers bypass antigen processing and enhance the immune response to low affinity antigens.

Authors:  Lijin Li; John M Herndon; Steven M Truscott; Ted H Hansen; Timothy P Fleming; Peter Goedegebuure; William E Gillanders
Journal:  Vaccine       Date:  2010-02-23       Impact factor: 3.641

Review 5.  Basic and translational applications of engineered MHC class I proteins.

Authors:  Ted H Hansen; Janet M Connolly; Keith G Gould; Daved H Fremont
Journal:  Trends Immunol       Date:  2010-09-09       Impact factor: 16.687

6.  The peptide-receptive transition state of MHC class I molecules: insight from structure and molecular dynamics.

Authors:  Michael G Mage; Michael A Dolan; Rui Wang; Lisa F Boyd; Maria Jamela Revilleza; Howard Robinson; Kannan Natarajan; Nancy B Myers; Ted H Hansen; David H Margulies
Journal:  J Immunol       Date:  2012-06-29       Impact factor: 5.422

7.  Amino-terminal extended peptide single-chain trimers are potent synthetic agonists for memory human CD8+ T cells.

Authors:  Beatriz M Carreno; Michelle Becker-Hapak; Megan Chan; Wen-Rong Lie; Xiaoli Wang; Ted H Hansen; Gerald P Linette
Journal:  J Immunol       Date:  2012-05-09       Impact factor: 5.422

8.  Introduction of a point mutation into an HLA class I single-chain trimer induces enhancement of CTL priming and antitumor immunity.

Authors:  Masanori Matsui; Masaaki Kawano; Sho Matsushita; Toshitaka Akatsuka
Journal:  Mol Ther Methods Clin Dev       Date:  2014-07-02       Impact factor: 6.698

9.  Intrinsic Folding Properties of the HLA-B27 Heavy Chain Revealed by Single Chain Trimer Versions of Peptide-Loaded Class I Major Histocompatibility Complex Molecules.

Authors:  Izabela Lenart; Linh-Huyen Truong; Dinh Dung Nguyen; Olga Rasiukienė; Edward Tsao; Jonathan Armstrong; Pankaj Kumar; Kirsty McHugh; Branca I Pereira; Balraj S Maan; Malgorzata A Garstka; Paul Bowness; Neil Blake; Simon J Powis; Keith Gould; Darren Nesbeth; Antony N Antoniou
Journal:  Front Immunol       Date:  2022-07-25       Impact factor: 8.786

10.  An optimized single chain TCR scaffold relying on the assembly with the native CD3-complex prevents residual mispairing with endogenous TCRs in human T-cells.

Authors:  Diana Knies; Sebastian Klobuch; Shao-An Xue; Matthias Birtel; Hakim Echchannaoui; Oezlem Yildiz; Tana Omokoko; Philippe Guillaume; Pedro Romero; Hans Stauss; Ugur Sahin; Wolfgang Herr; Matthias Theobald; Simone Thomas; Ralf-Holger Voss
Journal:  Oncotarget       Date:  2016-04-19
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.